13-May-2024
No headlines found.
Cellectis Announces Completion of the Additional Equity Investment by AstraZeneca
Globe Newswire (Mon, 6-May 2:00 AM ET)
Cellectis Appoints Arthur Stril as Interim Chief Financial Officer
Globe Newswire (Thu, 2-May 4:30 PM ET)
Cellectis Reports Financial Results for the Fourth Quarter and Full Year 2023
Globe Newswire (Mon, 29-Apr 4:46 PM ET)
Globe Newswire (Mon, 22-Apr 4:30 PM ET)
Globe Newswire (Wed, 10-Apr 4:30 PM ET)
Globe Newswire (Mon, 8-Apr 4:30 PM ET)
Cellectis SA is a clinical stage biotechnological company, employing the core proprietary technologies to develop products based on gene-editing, with a portfolio of allogeneic Chimeric Antigen Receptor T-cells, or UCART, product candidates in the field of immuno-oncology and gene-edited hematopoietic stem and progenitor cells, or HSPC, product candidates in other therapeutic indications.
Cellectis S.A. - American Depositary Shares trades on the NASDAQ stock market under the symbol CLLS.
As of May 13, 2024, CLLS stock price declined to $2.97 with 12,446 million shares trading.
CLLS has a beta of 5.87, meaning it tends to be more sensitive to market movements. CLLS has a correlation of 0.33 to the broad based SPY ETF.
CLLS has a market cap of $213.70 million. This is considered a Small Cap stock.
Last quarter Cellectis S.A. - American Depositary Shares reported $2 million in Revenue and -$.57 earnings per share. This fell short of revenue expectation by $-14 million and missed earnings estimates by -$.35.
In the last 3 years, CLLS stock traded as high as $16.86 and as low as $.96.
The top ETF exchange traded funds that CLLS belongs to (by Net Assets): APIE, AVDE.
CLLS has outperformed the market in the last year with a price return of +54.7% while the SPY ETF gained +27.8%. However, in the short term, CLLS had mixed performance relative to the market. It has underperformed in the last 3 months, returning -2.9% vs +4.3% return in SPY. But in the last 2 weeks, CLLS shares have fared better than the market returning +18.5% compared to SPY +2.5%.
CLLS support price is $2.88 and resistance is $3.24 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that CLLS stock will trade within this expected range on the day.